**Effective Exon Skipping and Dystrophin Restoration by 29-O-Methoxyethyl Antisense Oligonucleotide in Dystrophin-Deficient Mice**

Duchenne muscular dystrophy (DMD) is a severe, progressive muscle-wasting disease caused by mutations in the DMD gene, leading to the absence of functional dystrophin protein. Antisense oligonucleotide (AO)-mediated exon skipping has emerged as a promising therapeutic strategy to restore the reading frame and generate a truncated but functional dystrophin protein. In this study, we investigated the efficacy of 2′-O-methoxyethyl phosphorothioate (MOE PS) antisense oligonucleotides in inducing exon skipping and dystrophin restoration in both cultured mdx myoblasts and in vivo using mdx mice. We compared MOE AOs of varying lengths and backbone chemistries with conventional 2′-O-methyl phosphorothioate (29OmePS) AOs.

In vitro experiments demonstrated that 25-mer MOE PS AOs induced significantly higher exon 23 skipping efficiency in H2K mdx myoblasts compared to shorter MOE variants and 29OmePS AOs. Dose-response analysis revealed that MOE25(PS) achieved near-maximal exon skipping at 500 nM, with no further improvement at 1 μM, indicating saturation of activity.8-Hydroxyoctanoic acid manufacturer In contrast, MOE25(PO) required higher concentrations to achieve similar levels, suggesting superior stability and binding affinity conferred by the phosphorothioate backbone.9,10-Bis((E)-2-(pyridin-4-yl)vinyl)anthracene Formula Time-course studies confirmed that peak exon skipping occurred at 48 hours post-transfection, consistent with previous findings on AO kinetics.

To assess cellular uptake, fluorescence-labeled MOE25(PS) and 29OmePS AOs were transfected into H2K mdx cells. Flow cytometry and fluorescence microscopy showed significantly greater intracellular accumulation of MOE25(PS), correlating with its enhanced exon-skipping performance.PMID:34740703 This suggests that improved cellular delivery may underlie the increased therapeutic potency of MOE PS AOs.

In vivo evaluation was conducted via single intramuscular injection of 5 μg of each AO into the tibialis anterior (TA) muscle of adult mdx mice. Two weeks post-injection, immunohistochemistry revealed robust dystrophin expression in MOE25(PS)-treated muscles, with an average of 237 ± 23 dystrophin-positive fibers per section—significantly higher than those treated with MOE25(PO), MOE20(PS), or 29OmePS. RT-PCR analysis confirmed up to 10% exon 23 skipping in MOE25(PS)-treated samples, while Western blotting detected up to 20% of normal dystrophin levels in TA muscle lysates, far exceeding results from other groups.

These findings demonstrate that 25-mer MOE PS AOs are highly effective in promoting exon skipping and restoring dystrophin in dystrophin-deficient mouse models. The superior performance is likely due to enhanced cellular uptake, nuclease resistance, and target affinity. Given the structural similarity between MOE and 29OmePS AOs—and the ongoing clinical development of the latter—these results suggest MOE PS chemistry offers a compelling alternative for systemic DMD therapy. Future studies should explore systemic delivery routes and long-term safety to advance MOE PS AOs toward clinical application.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com